Skip to main content

PRESS RELEASES
NEWS
Stay up to date with our most recent news
  • Uvax Bio Announces Dosing of First Participant in Phase 1 Clinical Trial Evaluating Two Vaccines to Prevent HIV-1 Infection
    News
    January 30, 2024 at 2:00 PM

    Uvax Bio, LLC, a privately held, clinical-stage vaccine company utilizing rational and computational biology to design and deliver novel 1c-SApNP® protein-based vaccines, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating the Company’s HIV-1 vaccine candidates, UVAX-1107 and UVAX-1197, in healthy volunteers in Australia.

  • Uvax Bio Receives Approval to Initiate a Phase 1 Clinical Trial of Novel HIV-1 Protein Nanoparticle Vaccine Candidates in Australia.
    News
    December 19, 2023 at 9:30 AM

    Uvax Bio, a privately held, clinical-stage vaccine company, today announced acknowledgement from Australian Therapeutic Goods Administration and approval from the Human Research Ethics Committee (HREC) to conduct a Phase 1 study of Uvax Bio's HIV-1 vaccine candidates in healthy volunteers in Australia. Uvax Bio will work with their Australia-based clinical research partners Avance Clinical and the Nucleus Network study site to initiate this study in January 2024.

  • Uvax Bio to give a Preclinical Development Update on its HIV-1 Vaccine at the World Vaccine Congress – West Coast 2023
    News
    November 28, 2023 at 3:00 AM

    Dr. Jiang Zhu, Associate Professor of Integrative Structural and Computational Biology at Scripps Research, and Co-founder of Uvax Bio, LLC will be presenting a review of the development of Uvax Bio’s HIV-1 vaccine candidates including the latest results from the company’s preclinical studies confirming safety and immunogenicity in rodent models. The presentation will be during the World Vaccine Congress – West Coast in Santa Clara, California on November 30th.

  • IUPAC Selects Glycan Trimming Technology used in Uvax Bio’s HIV-1 Vaccine Design and Manufacturing as one of the Top Ten Emerging Technologies in Chemistry for 2023
    News
    November 1, 2023 at 1:30 PM

    The International Union of Pure and Applied Chemistry (IUPAC) has selected the glycan trimming technology used by Prof. Jiang Zhu of Scripps Research, Co-founder and Chief Scientific Officer of Uvax Bio in his innovative design of HIV-1 vaccines to improve immune recognition as one of the Top Ten Emerging Technologies in Chemistry for 2023.

  • Katalin Karikó and Drew Weissman, Penn’s Historic mRNA Vaccine Research Team, Win 2023 Nobel Prize in Medicine
    News
    October 2, 2023 at 1:30 PM

    Uvax Bio would like to congratulate Drew Weissman and Katalin Kariko at Penn on their Nobel prize for their mRNA research. Dr. Weissman has been a Scientific Advisory Board member at Uvax Bio since inception.

  • Uvax Bio Appoints Pedro Garbes, MD., as Vice President, Global Medical Lead
    News
    September 13, 2023 at 9:30 AM

    Pedro Garbes, MD., has joined the company as Vice President, Global Medical Lead. Dr. Garbes joins Uvax Bio at a key inflection point as the company’s recombinant protein nanoparticle vaccines are advancing in development.

  • Uvax Bio Announces Publication of Results from Preclinical Studies of HIV Vaccine Candidates
    News
    April 26, 2023 at 7:30 AM
    Uvax Bio, LLC, a privately held, preclinical-stage vaccine company, today announced that its HIV vaccine candidates have shown significant improvement in immune response compared with current vaccine strategies, according to results from preclinical studie...
  • Uvax-2129, a recombinant protein nanoparticle vaccine, Uvax Bio’s answer to COVID-19, shows great promise against variants of concern
    News
    December 3, 2021 at 3:00 AM

    Uvax-2129, a recombinant protein nanoparticle vaccine, as Uvax Bio’s answer to COVID-19, shows great promise against multiple variants of...

  • Reshaping The Vaccine Manufacturing Paradigm
    News
    March 22, 2021 at 3:00 AM
    Uvax Bio’s unconventional approach brings a heretofore ignored physical component to vaccine design. Co-founders Dr. Ji Li and Jiang Zhu share why they think their platform is poised to revolutionize vaccine development, manufacturing, and distribution.Lau...